<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22304" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Glucagonoma Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sandhu</surname>
            <given-names>Sartaj</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sartaj Sandhu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22304.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Glucagonomas are neuroendocrine tumors of the pancreatic islets that secrete glucagon. Glucagonoma syndrome occurs due to the effects of elevated glucagon levels secreted by the tumor. The first case was described in 1942 by Becker et al. in a 45-year-old woman presenting with widespread dermatitis, weight loss, glossitis, and abnormal glucose tolerance associated with an islet cell neoplasm of the pancreas on autopsy specimen. In 1966, McGavran and colleagues identified the classic symptoms of mild diabetes and dermatitis along with elevated glucagon levels related to a metastatic alpha cell tumor of the pancreatic islets. This activity highlights the clinical presentation, evaluation, and management of glucagonomas and highlights the role of the interprofessional team in caring for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the symptoms of glucagonomas.</p></list-item><list-item><p>Describe laboratory tests and imaging studies used to diagnose glucagonomas.</p></list-item><list-item><p>Explain the management and requisite follow up for glucagonomas.</p></list-item><list-item><p>Outline the significance of a well-integrated, interprofessional approach to the medical and surgical management of glucagonomas.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22304&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22304">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22304.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Glucagonomas are neuroendocrine tumors of the pancreatic islets that secrete glucagon. Glucagonoma syndrome occurs due to the effects of elevated glucagon levels secreted by the tumor. The first case was described in 1942 by Becker et al. in a 45-year-old woman presenting with widespread dermatitis, weight loss, glossitis, and abnormal glucose tolerance associated with an islet cell neoplasm of the pancreas on autopsy specimen<xref ref-type="bibr" rid="article-22304.r1">[1]</xref>. IN 1966, McGavran and colleagues identified the classic symptoms of mild diabetes and dermatitis along with elevated glucagon levels related to a metastatic alpha cell tumor of the pancreatic islets<xref ref-type="bibr" rid="article-22304.r2">[2]</xref>. This review highlights the clinical presentation and management of glucagonomas.</p>
      </sec>
      <sec id="article-22304.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Glucagonomas are neuroendocrine tumors originating from multipotential stem cells of endodermal origin. They arise from the alpha cells of the islets in the pancreas. Most glucagonomas are solitary. However, less than 10% of them have been associated with multiple endocrine neoplasia 1 syndrome (MEN1)<xref ref-type="bibr" rid="article-22304.r3">[3]</xref>.</p>
      </sec>
      <sec id="article-22304.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Glucagonomas are sporadic and rare.&#x000a0;The annual occurrence is 0.01 to 0.1 new cases per 100,000<xref ref-type="bibr" rid="article-22304.r4">[4]</xref>. They are typically large (greater than 3 cm) and located mainly in the tail or the body of the pancreas due to the high prevalence of alpha cells in this area. Over 50% are metastatic at the time of diagnosis. The incidence of glucagonoma in males and females is similar. Most patients with glucagonoma present in the fifth to sixth decade of life.</p>
      </sec>
      <sec id="article-22304.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Glucagon is a single-chain polypeptide made up of 29 amino acids that are derived from a larger precursor peptide, which is cleaved upon secretion. The main site of glucagon production is pancreatic alpha-islet cells, which secrete glucagon in response to hypoglycemia, amino acids, gastric inhibitory peptide, and ghrelin. Glucagon acts in the liver to increase glycogenolysis and gluconeogenesis by stimulating the cAMP pathway resulting in an elevation of plasma glucose. The secretion of glucagon is inhibited by hyperglycemia, insulin, somatostatin, and GLP-1<xref ref-type="bibr" rid="article-22304.r5">[5]</xref>. It also causes relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon. The other actions of glucagon include stimulation of lipolysis.</p>
        <p>Excessive secretion of glucagon from the tumor leads to the glucagonoma syndrome. Classic glucagonoma syndrome consists of weight loss, necrolytic migratory erythema (NME), diabetes, and mucosal abnormalities including stomatitis, cheilitis, and glossitis<xref ref-type="bibr" rid="article-22304.r6">[6]</xref>. The precise etiology of NME is not known, but it is thought secondary to a combination of poor nutrition, low zinc, and amino acid levels. Diabetes results secondary to the direct effects of glucagon.&#x000a0;Diarrhea may occur from increased glucagon levels and co-secretion of gastrin, VIP, serotonin, or calcitonin.</p>
      </sec>
      <sec id="article-22304.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Glucagonoma syndrome also goes by the acronym 4D syndrome, consisting of dermatosis, diabetes, deep vein thrombosis, and depression<xref ref-type="bibr" rid="article-22304.r7">[7]</xref>.</p>
        <list list-type="bullet">
          <list-item>
            <p>The dermatoses associated with glucagonoma syndrome is called necrolytic migratory erythema (NME). It was first described by Wilkinson<xref ref-type="bibr" rid="article-22304.r8">[8]</xref>. It is present in up to 90% of the patients. It is widespread, with main areas of involvement being perioral, perigenital regions and the extremities. NME often starts as pruritic and painful erythematic papules or plaques which gradually enlarge and coalesce to form bullous lesions. Mucosal involvement presents in the form of angular cheilitis, glossitis, stomatitis, and blepharitis<xref ref-type="bibr" rid="article-22304.r9">[9]</xref>. Patients may also have hair loss and nail dystrophy.</p>
          </list-item>
          <list-item>
            <p>Weight loss occurs in about 90% of the patients with glucagonoma syndrome and is also one of the presenting features.</p>
          </list-item>
          <list-item>
            <p>Diabetes mellitus is present in nearly 80% of the patients. It is mostly mild as beta cell function of the pancreas is preserved and hence the production of insulin-mitigating ketoacidosis.</p>
          </list-item>
          <list-item>
            <p>Deep vein thrombosis is noted in nearly 50% of the patients. Patients with the unexplained thromboembolic disease should undergo a thorough history, physical and evaluation for the possibility of glucagonoma. It can occasionally present as pulmonary embolism which can be fatal.</p>
          </list-item>
          <list-item>
            <p>Depression, occurring in about 50% of the patients, may be related to the chronic dermatosis. Other neuropsychiatric manifestations include dementia, psychosis, agitation, hyperreflexia, ataxia, paranoid delusions, and proximal muscle weakness.</p>
          </list-item>
          <list-item>
            <p>Chronic diarrhea is seen in about 30% of the patients with glucagonoma syndrome.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22304.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Glucagonoma should be suspected in patients with NME associated with or without the other symptoms discussed above.</p>
        <list list-type="bullet">
          <list-item>
            <p>A fasting plasma glucagon level should be drawn. Fasting plasma glucagon levels are abnormally elevated usually greater than 500 pg/mL. Normal fasting plasma glucagon levels are less than 150 pg/mL. It is important to note that different glucagon assays may exhibit variable cross-reactivity with different isoforms of glucagon, not all of which (nearly 70%) are biologically active. Serial measurements should, therefore, always be performed using the same assay directed against the C-terminus.</p>
          </list-item>
          <list-item>
            <p>Serum concentrations of amino acids and zinc should be checked to evaluate the nutritional status. The laboratory abnormalities with glucagonoma can include hypoaminoacidemia&#x000a0;(due to targeting of amino acids into metabolic pathways in the liver by excessive hyperglucagonemia) and low zinc levels.</p>
          </list-item>
          <list-item>
            <p>A complete blood count (CBC) should be obtained to check for concurrent normocytic anemia. A comprehensive metabolic panel (CMP) should be checked to detect other metabolic abnormalities.</p>
          </list-item>
          <list-item>
            <p>Obtaining serum parathyroid hormone, gastrin, insulin, pancreatic polypeptide, serotonin, vasoactive intestinal polypeptide (VIP), prolactin and ACTH levels is important as glucagonoma can rarely be associated with the MEN1 syndrome.</p>
          </list-item>
          <list-item>
            <p>Skin biopsy of the NME lesion shows small bullae consisting of acantholytic epidermal cells along with lymphocytic and neutrophilic infiltrate. The dermis contains a perivascular lymphocytic infiltrate with an intact epidermis.</p>
          </list-item>
        </list>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>Tumor localization is typically started with a helical multiphasic contrast-enhanced CT scan.&#x000a0; The sensitivity of multiphasic CT scans is significantly&#x000a0;high at greater than 80% for detecting intrapancreatic neuroendocrine tumors.</p>
        <p>MRI is performed in case of indeterminate lesions and may have a better sensitivity to detect liver metastases.</p>
        <p>Glucagonomas express abundant somatostatin receptors as compared to other pancreatic neuroendocrine tumors. Hence, they are suitable for localization using somatostatin analogues like octreotide. Somatostatin receptor scintigraphy (SRS) was positive in 97% of glucagonoma patients, as noted in a study by Kindmark et al.<xref ref-type="bibr" rid="article-22304.r10">[10]</xref>. It also has the advantage of detecting small, occult metastases within and outside of the abdomen and hence, helpful in the staging of the tumor.</p>
        <p>Functional PET imaging technique with DOTA peptides like DOTATATE, DOTANOC, DOTATOC could be used in the localization of non-metastatic tumors. They offer higher spatial resolution as compared to the SRS and provide higher sensitivity, particularly in the detection of smaller lesions.</p>
      </sec>
      <sec id="article-22304.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Initial Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Surgical resection is the only curative option in a minority of cases where the tumor is localized at the time of diagnosis<xref ref-type="bibr" rid="article-22304.r11">[11]</xref>. The type of pancreatic resection is determined after careful assessment of the site and size of the tumor.</p>
          </list-item>
          <list-item>
            <p>Nutritional support includes total parenteral nutrition, supplementation of amino acids and zinc supplementation to reverse the effects of malnutrition and catabolic effects of weight loss from the glucagon.</p>
          </list-item>
          <list-item>
            <p>Antibiotics, zinc replacement, and steroids may help with the improvement of NME.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Somatostatin analogs like octreotide and lanreotide help to reverse the effects of glucagon excess as well as inhibit secretion of glucagon <xref ref-type="bibr" rid="article-22304.r12">[12]</xref>.&#x000a0;Octreotide LAR and Lanreotide have been reported to significantly lengthen the time to tumor progression<xref ref-type="bibr" rid="article-22304.r13">[13]</xref>,<xref ref-type="bibr" rid="article-22304.r14">[14]</xref>. It also improves NME, diabetes, diarrhea, and neurological symptoms.</p>
          </list-item>
          <list-item>
            <p>Prophylactic anticoagulant therapy, for example, heparin to prevent deep venous thrombosis is mandatory for all patients during the perioperative period.</p>
          </list-item>
        </list>
        <p>
<bold>Management of progressive/Metastatic Disease</bold>
</p>
        <p>The most common site of metastasis is liver. Hepatic resection has been recommended in patients without widespread liver involvement, diffuse extrahepatic metastases, and decreased liver function<xref ref-type="bibr" rid="article-22304.r15">[15]</xref>. Resection has led to a decrease in glucagon levels and significant improvement of NME.</p>
        <p>Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is a palliative method used in patients with symptomatic hepatic metastases and are not candidates for hepatic resection<xref ref-type="bibr" rid="article-22304.r16">[16]</xref>.</p>
        <p>Radiofrequency ablation applies to smaller lesions (typically smaller than 3 cm) and is less invasive than hepatic resection or hepatic arterial embolization. It can be used as in conjunction&#x000a0;with surgical resection, or as a primary treatment technique for the hepatic metastases<xref ref-type="bibr" rid="article-22304.r17">[17]</xref>.</p>
        <p>Combination chemotherapy with streptozocin, 5-fluorouracil or Temozolomide containing regimens, often in combination with a somatostatin analog have been used in patients with large tumors and enlarging metastases. The use of systemic chemotherapy is limited to patients with advanced disease<xref ref-type="bibr" rid="article-22304.r18">[18]</xref>.</p>
        <p>Molecular targeted agents such as&#x000a0;sunitinib, a tyrosine kinase inhibitor, and everolimus, a mTOR inhibitor are approved in the United States for treatment of advanced, well-differentiated, pancreatic neuroendocrine tumors including glucagonomas<xref ref-type="bibr" rid="article-22304.r19">[19]</xref>,<xref ref-type="bibr" rid="article-22304.r20">[20]</xref>.</p>
        <p>Peptide receptor radionuclide therapy (PRRT), also known as radioisotope therapy, is a novel method being used for the management of neuroendocrine tumors. The high expression of somatostatin receptors in glucagonoma provides an opportunity for the use of PRRT<xref ref-type="bibr" rid="article-22304.r21">[21]</xref>.</p>
      </sec>
      <sec id="article-22304.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Fasting plasma glucagon levels may be elevated in other conditions like acute trauma, diabetes mellitus, burn injury, sepsis, renal failure, &#x000a0;cirrhosis, pancreatitis or Cushing syndrome. Though the fasting plasma glucagon levels in these conditions are elevated, it is typically less than 500 pg/mL. A rare disorder due to an inactivation mutations defect in the glucagon receptor gene&#x000a0;that causes pancreatic alpha cell hyperplasia, an elevation of glucagon without symptoms is called Mahvash disease<xref ref-type="bibr" rid="article-22304.r22">[22]</xref>.</p>
          </list-item>
          <list-item>
            <p>NME is not specific to glucagonoma and can also be seen in with chronic liver disease, inflammatory bowel disease, pancreatitis, heroin abuse, jejunal and rectal adenocarcinoma, and myelodysplastic syndrome.</p>
          </list-item>
          <list-item>
            <p>NME-like lesions have been associated with essential fatty acid deficiency, zinc deficiency (acrodermatitis enteropathica), and the dermatosis of protein-calorie malnutrition.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22304.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Glucagonomas are typically slow growing; however, they are usually advanced by the time of diagnosis. The predictors of survival are dependent on age, tumor grade, and distant metastases. The cure is rarely achieved once the tumor is metastatic.</p>
        <p>As per the National Comprehensive Cancer Network guidelines, the post-resection follow up includes history and physical examination, serum glucagon level, CT or MRI in the initial 3 to 12-month period.&#x000a0; After 1 year, it is recommended to follow the same measures every 6 to 12 months up to a maximum of 10 years.</p>
      </sec>
      <sec id="article-22304.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Glucagonoma syndrome is difficult to diagnose and once diagnosed a challenge to manage. An interprofessional&#x000a0;team of nurses, primary care providers, and specialists must work together to monitor the patient as they are at risk&#x000a0;for developing dermatosis, diabetes, deep vein thrombosis, and depression. [Level V]</p>
      </sec>
      <sec id="article-22304.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22304&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22304">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/glucagonoma-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22304">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22304/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22304">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22304.s13">
        <title>References</title>
        <ref id="article-22304.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braverman</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>"Cutaneous manifestations of internal malignant tumors" by Becker, Kahn and Rothman, June 1942. Commentary: Migratory necrolytic erythema.</article-title>
            <source>Arch Dermatol</source>
            <year>1982</year>
            <month>Oct</month>
            <volume>118</volume>
            <issue>10</issue>
            <fpage>784</fpage>
            <page-range>784-98</page-range>
            <pub-id pub-id-type="pmid">6127984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGavran</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Recant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Polk</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kilo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>A glucagon-secreting alpha-cell carcinoma of the pancreas.</article-title>
            <source>N Engl J Med</source>
            <year>1966</year>
            <month>Jun</month>
            <day>23</day>
            <volume>274</volume>
            <issue>25</issue>
            <fpage>1408</fpage>
            <page-range>1408-13</page-range>
            <pub-id pub-id-type="pmid">4286757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-53</page-range>
            <pub-id pub-id-type="pmid">23582916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Cadiot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Komminoth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scoazec</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sauvanet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kianmanesh</surname>
                <given-names>R</given-names>
              </name>
              <collab>Barcelona Consensus Conference participants</collab>
            </person-group>
            <article-title>ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.</article-title>
            <source>Neuroendocrinology</source>
            <year>2012</year>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>98</fpage>
            <page-range>98-119</page-range>
            <pub-id pub-id-type="pmid">22261919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wewer Albrechtsen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Kuhre</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knop</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The biology of glucagon and the consequences of hyperglucagonemia.</article-title>
            <source>Biomark Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>1141</fpage>
            <page-range>1141-1151</page-range>
            <pub-id pub-id-type="pmid">27611762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wermers</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Fatourechi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wynne</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kvols</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>The glucagonoma syndrome. Clinical and pathologic features in 21 patients.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>53</fpage>
            <page-range>53-63</page-range>
            <pub-id pub-id-type="pmid">8606627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Glucagon &#x00026; Glucagonoma Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">25905270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkinson</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic migratory erythema with pancreatic carcinoma.</article-title>
            <source>Proc R Soc Med</source>
            <year>1971</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>12</issue>
            <fpage>1197</fpage>
            <page-range>1197-8</page-range>
            <pub-id pub-id-type="pmid">5131260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolliver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>642</fpage>
            <page-range>642-645</page-range>
            <pub-id pub-id-type="pmid">29450880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kindmark</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sundin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Granberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dunder</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Skogseid</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Janson</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Welin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.</article-title>
            <source>Med Oncol</source>
            <year>2007</year>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>330</fpage>
            <page-range>330-7</page-range>
            <pub-id pub-id-type="pmid">17873310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knigge</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Niederle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nieveen van Dijkum</surname>
                <given-names>EJM</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>UF</given-names>
              </name>
              <name>
                <surname>Pascher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scoazec</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kianmanesh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <collab>Antibes Consensus Conference participants</collab>
            </person-group>
            <article-title>ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.</article-title>
            <source>Neuroendocrinology</source>
            <year>2017</year>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-265</page-range>
            <pub-id pub-id-type="pmid">28237989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grozinsky-Glasberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shimon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>701</fpage>
            <page-range>701-20</page-range>
            <pub-id pub-id-type="pmid">18524947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rinke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wittenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schade-Brittinger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aminossadati</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ronicke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>R</given-names>
              </name>
              <collab>PROMID Study Group</collab>
            </person-group>
            <article-title>Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.</article-title>
            <source>Neuroendocrinology</source>
            <year>2017</year>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-32</page-range>
            <pub-id pub-id-type="pmid">26731483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caplin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pavel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Lanreotide in metastatic enteropancreatic neuroendocrine tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Oct</month>
            <day>16</day>
            <volume>371</volume>
            <issue>16</issue>
            <fpage>1556</fpage>
            <page-range>1556-7</page-range>
            <pub-id pub-id-type="pmid">25317881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McEntee</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Nagorney</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kvols</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Moertel</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Cytoreductive hepatic surgery for neuroendocrine tumors.</article-title>
            <source>Surgery</source>
            <year>1990</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>1091</fpage>
            <page-range>1091-6</page-range>
            <pub-id pub-id-type="pmid">1701060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennedy</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Hepatic-directed Therapies in Patients with Neuroendocrine Tumors.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>193</fpage>
            <page-range>193-207</page-range>
            <pub-id pub-id-type="pmid">26614377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liaw</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Sep</month>
            <day>01</day>
            <volume>113</volume>
            <issue>5</issue>
            <fpage>921</fpage>
            <page-range>921-9</page-range>
            <pub-id pub-id-type="pmid">18618495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rinke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Falkerby</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gorbounova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kulke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lombard-Bohas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sorbye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Garcia-Carbonero</surname>
                <given-names>R</given-names>
              </name>
              <collab>Antibes Consensus Conference Participants</collab>
              <collab>Antibes Consensus Conference participants</collab>
            </person-group>
            <article-title>ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents.</article-title>
            <source>Neuroendocrinology</source>
            <year>2017</year>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-280</page-range>
            <pub-id pub-id-type="pmid">28351033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raymond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raoul</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Borbath</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lombard-Bohas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metrakos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vinik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>H&#x000f6;rsch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hammel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiedenmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patyna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Blanckmeister</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Feb</month>
            <day>10</day>
            <volume>364</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-13</page-range>
            <pub-id pub-id-type="pmid">21306237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bohas</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hobday</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Okusaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Tomassetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pavel</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hoosen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lincy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>K</given-names>
              </name>
              <collab>RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group</collab>
            </person-group>
            <article-title>Everolimus for advanced pancreatic neuroendocrine tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Feb</month>
            <day>10</day>
            <volume>364</volume>
            <issue>6</issue>
            <fpage>514</fpage>
            <page-range>514-23</page-range>
            <pub-id pub-id-type="pmid">21306238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Teunissen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kooij</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>van Eijck</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Erion</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>417</fpage>
            <page-range>417-22</page-range>
            <pub-id pub-id-type="pmid">12634971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22304.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.</article-title>
            <source>Chin J Cancer</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>312</fpage>
            <page-range>312-24</page-range>
            <pub-id pub-id-type="pmid">23237225</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
